Trial Profile
Phase II trial to assess the efficacy of Iressa (gefitinib) 500 mg/day in patients with breast cancer who have failed tamoxifen or have an oestrogen receptor negative tumour and would be considered for systemic therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2008
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 02 Apr 2008 New trial record.